{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:11:56Z","timestamp":1787163116941,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s12325-020-01264-7","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T11:03:02Z","timestamp":1583146982000},"page":"1536-1549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical Practice Experience with HyQvia in Adults Using Alternative Dosing Regimens and Pediatric Patients: A Retrospective Study"],"prefix":"10.1007","volume":"37","author":[{"name":"HyQvia Experience Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Wasserman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"issue":"1","key":"1264_CR1","first-page":"13","volume":"21","author":"B Eley","year":"2008","unstructured":"Eley B. An update of the primary antibody disorders. Curr Allergy Clin Immunol. 2008;21(1):13\u20139.","journal-title":"Curr Allergy Clin Immunol"},{"issue":"6","key":"1264_CR2","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s10875-012-9740-x","volume":"32","author":"RL Wasserman","year":"2012","unstructured":"Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol. 2012;32(6):1153\u201364.","journal-title":"J Clin Immunol"},{"issue":"8","key":"1264_CR3","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2165\/11209490-000000000-00000","volume":"72","author":"PL McCormack","year":"2012","unstructured":"McCormack PL. Immune globulin subcutaneous (human) 20%: in primary immunodeficiency disorders. Drugs. 2012;72(8):1087\u201397.","journal-title":"Drugs"},{"issue":"4","key":"1264_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40259-013-0044-3","volume":"27","author":"PL McCormack","year":"2013","unstructured":"McCormack PL. Immune globulin (human) 10% liquid: a review of its use in primary immunodeficiency disorders. BioDrugs. 2013;27(4):303\u2013400.","journal-title":"BioDrugs"},{"issue":"6","key":"1264_CR5","doi-asserted-by":"publisher","first-page":"1354.e4","DOI":"10.1016\/j.jaci.2010.02.040","volume":"125","author":"M Lucas","year":"2010","unstructured":"Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22\u00a0years. J Allergy Clin Immunol. 2010;125(6):1354.e4\u20131.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1264_CR6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"9","author":"OC Bruton","year":"1952","unstructured":"Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722\u20138.","journal-title":"Pediatrics"},{"issue":"3S","key":"1264_CR7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","volume":"139","author":"EE Perez","year":"2017","unstructured":"Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1\u201346.","journal-title":"J Allergy Clin Immunol"},{"key":"1264_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/BF03259507","volume":"6","author":"A Gardulf","year":"1996","unstructured":"Gardulf A, Hammarstr\u00f6m L. Subcutaneous administration of immunoglobulins. Clin Immunother. 1996;6:108\u201316.","journal-title":"Clin Immunother"},{"issue":"1","key":"1264_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2004.02.002","volume":"112","author":"M Berger","year":"2004","unstructured":"Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112(1):1\u20137.","journal-title":"Clin Immunol"},{"issue":"3","key":"1264_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10875-011-9512-z","volume":"31","author":"RL Wasserman","year":"2011","unstructured":"Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31(3):323\u201331.","journal-title":"J Clin Immunol"},{"issue":"4","key":"1264_CR11","doi-asserted-by":"publisher","first-page":"951.e11","DOI":"10.1016\/j.jaci.2012.06.021","volume":"130","author":"RL Wasserman","year":"2012","unstructured":"Wasserman RL, Melamed I, Stein MR, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951\u20137.e11.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1264_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.iac.2008.07.001","volume":"28","author":"M Garcia-Lloret","year":"2008","unstructured":"Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin replacement therapy in children. Immunol Allergy Clin North Am. 2008;28(4):833\u201349.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"8760","key":"1264_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/0140-6736(91)90147-H","volume":"338","author":"A Gardulf","year":"1991","unstructured":"Gardulf A, Hammarstr\u00f6m L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338(8760):162\u20136.","journal-title":"Lancet"},{"issue":"4","key":"1264_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s10875-008-9180-9","volume":"28","author":"A Fasth","year":"2008","unstructured":"Fasth A, Nystr\u00f6m J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol. 2008;28(4):370\u20138.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1264_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","volume":"26","author":"U Nicolay","year":"2006","unstructured":"Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26(1):65\u201372.","journal-title":"J Clin Immunol"},{"issue":"Suppl 1","key":"1264_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2249.2009.04027.x","volume":"158","author":"S Misbah","year":"2009","unstructured":"Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158(Suppl 1):51\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"1264_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","volume":"26","author":"HD Ochs","year":"2006","unstructured":"Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26(3):265\u201373.","journal-title":"J Clin Immunol"},{"issue":"5","key":"1264_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/01.NAN.0000292572.70387.17","volume":"30","author":"RC Yocum","year":"2007","unstructured":"Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J Infus Nurs. 2007;30(5):293\u20139.","journal-title":"J Infus Nurs"},{"issue":"2","key":"1264_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1185\/03007990903432900","volume":"26","author":"G Harb","year":"2010","unstructured":"Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin. 2010;26(2):279\u201388.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"1264_CR20","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1542\/peds.2008-3588","volume":"124","author":"CH Allen","year":"2009","unstructured":"Allen CH, Etzwiler LS, Miller MK, et al. Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics. 2009;124(5):e858\u201367.","journal-title":"Pediatrics"},{"issue":"6","key":"1264_CR21","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1089\/jpm.2007.0126","volume":"10","author":"JR Thomas","year":"2007","unstructured":"Thomas JR, Yocum RC, Haller MF, von Gunten CF. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. J Palliat Med. 2007;10(6):1312\u201320.","journal-title":"J Palliat Med"},{"issue":"10","key":"1264_CR22","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2217\/imt-2016-0066","volume":"8","author":"RL Wasserman","year":"2016","unstructured":"Wasserman RL, Melamed I, Kobrynski L, et al. Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability. Immunotherapy. 2016;8(10):1175\u201386.","journal-title":"Immunotherapy"},{"issue":"6","key":"1264_CR23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10875-016-0298-x","volume":"36","author":"RL Wasserman","year":"2016","unstructured":"Wasserman RL, Melamed I, Stein MR, et al. Long-term tolerability, safety, and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency. J Clin Immunol. 2016;36(6):571\u201382.","journal-title":"J Clin Immunol"},{"key":"1264_CR24","unstructured":"HYQVIA [prescribing information]. Westlake Village, CA: Baxalta US Inc. https:\/\/www.shirecontent.com\/PI\/PDFs\/HYQVIA_USA_ENG.pdf."},{"key":"1264_CR25","doi-asserted-by":"crossref","unstructured":"Rosenbach KP, Rabbat CJ, Rozen L, Hughes SM. Real-world use of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (IGHy; HYQVIA) in patients with primary immunodeficiency disorders (PID). Presented at: Clinical Immunology Society. 2016 April 14\u201317, Boston, MA.","DOI":"10.1016\/j.jaci.2015.12.853"},{"issue":"5","key":"1264_CR26","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/j.anai.2016.09.268","volume":"117","author":"P Gruenemeier","year":"2016","unstructured":"Gruenemeier P, Ernst C, White C, Duff K. Real-world pediatric experience with hyaluronidase-facilitated subcutaneous immunoglobulin (IGHY) infusion parameters [Abstract]. Ann Allergy Asthma Immunol. 2016;117(5):S98.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1264_CR27","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R1). June 1996. http:\/\/www.ich.org\/products\/guidelines\/efficacy\/efficacy-single\/article\/good-clinical-practice.html. Accessed Oct 8 2015."},{"issue":"5","key":"1264_CR28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2217\/imt.14.34","volume":"6","author":"RL Wasserman","year":"2014","unstructured":"Wasserman RL. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy. 2014;6(5):553\u201367.","journal-title":"Immunotherapy"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01264-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-020-01264-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01264-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T01:24:40Z","timestamp":1665969880000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-020-01264-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1264"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01264-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,2]]},"assertion":[{"value":"12 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}